Fig. 3.
(A) Western blotting study using biotinylated MoAbs 2E9 and 1H6. Lane 1 in each panel is CD34-Ig and lane 2 in each panel is a control fusion protein (CTLA4-Ig) that has the same murine IgG2A sequence as CD34-Ig. 1H6 and 2E9 recognize CD34-Ig but not CTLA4-Ig, indicating specific binding of 2E9 and 1H6 to the extracellular domain of CD34 as expressed in the fusion construct. (B) Western blots of cell lines ML1 (CD34−), ML3, and 1390 (both CD34+) using 2E9 and RPαCD34. The band for CD34 (∼110 kD) is indicated by the arrow. The other bands present on these blots were also detected in control experiments using only the second-stage reagents.

(A) Western blotting study using biotinylated MoAbs 2E9 and 1H6. Lane 1 in each panel is CD34-Ig and lane 2 in each panel is a control fusion protein (CTLA4-Ig) that has the same murine IgG2A sequence as CD34-Ig. 1H6 and 2E9 recognize CD34-Ig but not CTLA4-Ig, indicating specific binding of 2E9 and 1H6 to the extracellular domain of CD34 as expressed in the fusion construct. (B) Western blots of cell lines ML1 (CD34), ML3, and 1390 (both CD34+) using 2E9 and RPαCD34. The band for CD34 (∼110 kD) is indicated by the arrow. The other bands present on these blots were also detected in control experiments using only the second-stage reagents.

Close Modal

or Create an Account

Close Modal
Close Modal